Artiva Biotherapeutics, Inc. Additional Paid in Capital, Common Stock
Artiva Biotherapeutics, Inc. (ARTV) had Additional Paid in Capital, Common Stock of $726.59 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AdditionalPaidInCapitalCommonStock · last filed 2026-08-06
- 2026-06-30: Additional Paid in Capital, Common Stock $726.59M.
- 2026-03-31: Additional Paid in Capital, Common Stock $441.93M.
- 2025-12-31: Additional Paid in Capital, Common Stock $440.41M.
- 2025-09-30: Additional Paid in Capital, Common Stock $438.91M.
| Period end | Additional Paid in Capital, Common Stock |
|---|---|
| 2026-06-30 | $726.59M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $441.93M 10-Q · filed 2026-05-08 |
| 2025-12-31 | $440.41M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $438.91M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $437.29M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $435.77M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $433.45M 10-K · filed 2026-03-10 |
| 2024-09-30 | $431.24M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $21.90M 10-Q · filed 2024-08-29 |
| 2023-12-31 | $18.99M 10-K · filed 2025-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |